Premium
Maternal, fetal, and neonatal outcomes associated with long‐term use of corticosteroids during pregnancy
Author(s) -
AlSaad Doua,
Lindow Stephen,
Lee Ben H,
Tarannum Asma,
Abdulrouf Palli Valapila
Publication year - 2019
Publication title -
the obstetrician and gynaecologist
Language(s) - English
Resource type - Journals
eISSN - 1744-4667
pISSN - 1467-2561
DOI - 10.1111/tog.12556
Subject(s) - medicine , pregnancy , fetus , betamethasone , corticosteroid , dexamethasone , asthma , obstetrics , pediatrics , intensive care medicine , endocrinology , genetics , biology
Key content Antenatal corticosteroid use is strongly associated with reduced neonatal mortality and morbidity arising from preterm delivery. Betamethasone and dexamethasone are the corticosteroids of choice to enhance fetal lung maturation in this situation. Maternal medical conditions such as autoimmune diseases, asthma and allergies may necessitate long‐term use of corticosteroids during pregnancy. The maternal, fetal and neonatal effects in pregnant women using chronic corticosteroids are reviewed. The question as to whether the standard course of antenatal corticosteroids is necessary if preterm delivery is anticipated is discussed.Learning objectives To review the production of endogenous corticosteroids in pregnancy. To be aware of the effect of chronic corticosteroid use on fetal lung maturity during pregnancy. To appreciate the maternal, fetal and neonatal effects of exogenous corticosteroid use in pregnancy.Ethical issues Is the fluorinated antenatal corticosteroids course given for preterm delivery indicated in women using corticosteroids on a chronic basis? What are the fetal and neonatal outcomes of chronic corticosteroid use by the pregnant woman? How should women taking chronic corticosteroids be managed?